The 4000th eye tumour patient treated with protons at HZB
Overview: Number of patients treated with prontons at HZB from 1998 to 2020. © HZB/S. Kodalle
On 19 February 2021, the 4000th eye tumour patient received irradiation with protons, performed by a joint team from Helmholtz-Zentrum Berlin (HZB) and Charité - Universitätsmedizin Berlin. The number of patients treated in 2020 remained at the previous year's level despite the more difficult corona conditions. The treatment in Berlin-Wannsee is only available for uveal melanomas of the eye. The proton accelerator at HZB is the only therapy site for this disease in Germany.
For more than 20 years, Charité - Universitätsmedizin Berlin and Helmholtz-Zentrum Berlin (HZB) have jointly offered irradiation of eye tumours with protons. For this purpose, the HZB operates a proton accelerator, while the medical care of patients is provided by the Charité.
"We congratulate the joint team on this great success and thank them for doing everything they could under the difficult pandemic conditions to maintain the operation of the life-saving eye tumour therapy," says Prof. Bernd Rech, spokesman for the scientific management of HZB.
500 to 600 people contract malignant uveal melanoma in Germany every year. In 97 percent of cases, the tumour can be completely destroyed by irradiation with protons. In most cases, not only the eye but also the vision can be preserved to a satisfactory degree. Radiation with protons is a particularly effective method: the energy of the proton beam can be adjusted in such a way that practically only the tumour receives the radiation, while the surrounding healthy tissue is spared.
- Berlin Battery Lab: BAM, HZB and HU are conducting joint research on sodium batteriesThe Federal Institute for Materials Research and Testing (BAM), the Helmholtz Zentrum Berlin (HZB) and Humboldt-Universität zu Berlin (HU) today officially inaugurated the Berlin Battery Lab (BBL). At this new research platform, BAM, HZB and HU jointly develop and test resource-efficient battery technologies with a focus on sodium-based systems. Together, they develop new materials, investigate innovative cell chemistries, and produce battery prototypes. The research infrastructure of the Berlin Battery Lab is also open to external partners from science and industry and is designed to accelerate the transfer from research to application.
- Humboldt-Fellow at HZB Institute for Solar Fuels: Kayode Adesina AdegokeKayode Adesina Adegoke is a renowned chemist, affiliated with LAUTECH SDG 11 (Sustainable Cities and Communities Research Group), Department of Pure and Applied Chemistry, Ladoke Akintola University of Technology, Ogbomoso, Nigeria. He is collaborating with Matthew Mayer to investigate the degradation of electrocatalysts during electrochemical CO₂ reduction. The Alexander von Humboldt Fellowship enables him to stay at Helmholtz Zentrum Berlin up to 24 months.
- Protein crystallography at BESSY II: faster, better and more and more automaticMany diseases are linked to malfunctions of proteins in the organism. The three-dimensional architecture of these molecules is often highly complex, but it can provide valuable insights into biological processes and the development of drugs. X-ray diffraction at the MX beamlines of BESSY II can be used to decipher the 3D structure of proteins. To date, more than 5000 structures have been solved at the three MX beamlines. Here, we present a review and an outlook with Manfred Weiss, head of the research group for macromolecular crystallography.